BIOLASE to Present at the 7th Annual LD Micro Invitational

LOS ANGELES, CA / ACCESSWIRE / May 31, 2017 / BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will be presenting at the 7th annual LD Micro Invitational investor conference at 12:30 PM PDT, Wednesday, June 7, 2016. BIOLASE President and Chief Executive Officer, Harold C. Flynn, Jr., will be giving the presentation and meeting with investors.

A live webcast and a 90-day replay of the presentation will be available from LD Micro by clicking here or from BIOLASE on the Investor Events page of its website at http://www.biolase.com/Pages/Investors.aspx.

The conference will be held from June 6-7, 2017, at the Luxe Sunset Bel Air Hotel and will feature 180 small- and micro-cap companies.

In addition to a record number of companies making their LD Micro debuts this year, there are a record number of companies presenting for the first time in their company’s history.

LD Micro President, Chris Lahiji, said, “We are proud to have established LD as the venue that brings a big group of the most influential players from all segments of the market together under one roof to meet with a large number of exciting and innovative small- and micro-cap companies.”

To access the BIOLASE Inc. profile prepared by LD Micro, please click here: http://www.ldmicro.com/profile/BIOL

Profiles powered by LD Micro – News Compliments of ACCESSWIRE.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 210 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 34,200 laser systems to date in over 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets.

For updates and information on Waterlase® iPlus™, Waterlase Express™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and Waterlase® are registered trademarks of BIOLASE, Inc.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements made during BIOLASE’s presentation and its investor meetings at the 7th annual LD Micro Invitational investor conference in Los Angeles, CA (the “Meetings”), and in its representative’s answers to questions during the Meetings that refer to BIOLASE’s estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements its representatives make during the Meetings concerning BIOLASE’s strategic initiatives, anticipated financial performance and product launches. Attendees at the Meetings are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the dates of BIOLASE’s participation in the Meetings. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business including, among others, adverse changes in general economic and market conditions, competitive factors, uncertainty of customer acceptance of new product offerings, risks associated with managing the growth of the business, and those other risks and uncertainties that are described, from time-to-time, in the “Risk Factors” section of BIOLASE’s annual and quarterly reports filed with the Securities and Exchange Commission. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements made during its participation in the Conference.

Contacts:

DresnerAllenCaron
Michael Mason (Investors)
212-691-8087
mmason@dresnerallencaron.com

Rene Caron (Investors)
949-474-4300
rcaron@dresnerallencaron.com

Len Hall (Media)
949-474-4300
lhall@dresnerallencaron.com

SOURCE: BIOLASE, Inc.

ReleaseID: 464478